Ambulero is a regenerative gene and cell therapy spin-out from the University of Miami developing new ways to treat vascular tissue disease.
COMPANY: OUR TEAM
MANAGEMENT TEAM
Robert L. Buchanan
Robert L. Buchanan - serial entrepreneur and investor; Entrepreneur-in-Residence, University of Miami, co-founder Idogen AS (IDOGEN: Spotlight); early investor RhoVAC AS (RHOVAC: Spotlight); GC Avexxin AS, PhD. UCLA, Biology Fellow CalTech, former Associate GC Biogen Inc, Ventac Partners LLC, Boston
Chief Executive Officer
Carlton Anderson
Chief Operations Officer
30 years of experience in the healthcare industry, advancing pharmaceuticals and biologics to market including over 20 US & foreign products. Early in his career, Dr. Anderson was a professional baseball player with the Pittsburgh Pirates; MS Strategic Management, U North Texas, PhD U North Texas Health Science Center, Partner Ventac Partners, LLC Dallas/Fort Worth.
Robert L. Buchanan - serial entrepreneur and investor; Etrepreneur-in-residence, University of Miami, co-founder Idogen AS (IDOGEN: Spotlight); early investor RhoVAC AS (RHOVAC: Spotlight); GC Avexxin AS, PhD. UCLA, Biology Fellow CalTech, former Associate GC Biogen Inc, Ventac Partners LLC, Boston
Omaida Caridad Velazquez
Chief Medical Officer
Professor and Chair, DeWitt Daughtry Family Department of Surgery, David Kimmelman Endowed Chair in Vascular Surgery, Surgeon-in-Chief for UMHS Health System & Jackson Health System, Leonard. M. Miller School of Medicine, University of Miami. She is the PI of an NIH-funded basic science laboratory investigating vascular biology, angiogenesis and vasculogenesis. Dr. Velazquez is the author of 20 books/monographs, more than 100 journal articles, has received 35 funded research grants.
Zhao-Jun Liu
Chief Scientific Officer
Professor, University of Miami;
Dr. Liu focuses on using stem cells to improve blood circulation in patients with peripheral artery disease (PAD) and critical limb ischemia (CLI). Dr. Liu is leading efforts to understand the basic biology and uses of supercharged stem cells. He is leading our non-clinical work to IND for Ambulero’s gene and cell therapy programs.
Khemraj Hirani
Chief Regulatory Officer
>21 years of investigational drugs/biologics experience from bench to clinic. Principal strategic and regulatory consultant for clinical, scientific, and regulatory SME for the University of Miami Miller School of Medicine, PriZm Therapeutics, IGEA Pharma, Betalin Therapeutics, Eyepharma Inc, AAHRPP. Certified clinical (RPH), IRB (CIP), and Regulatory (RAC-US) professional dedicated to bringing novel therapies to market for unmet medical conditions.
BOARD
Randy Berholtz
Chair
Mesa Verde Venture Partners, executive level positions at Innovus Pharmaceuticals, Apricus Biosciences, ACON laboratories, Nanogen, Inglewood Ventures, LP, Ventac Partners LLC, San Diego
-
Member: Robert L. Buchanan (CEO)
OTHER MEMBERS: To be announced
BUSINESS ADVISORS
To be announced.
SCIENTIFIC ADVISORY BOARD
Gregory Landry
Chair
Head Division of Vascular Surgery, Professor of Surgery, Division of Vascular Surgery School of Medicine at the Oregon Health & Science University, Portland Oregon
Tim Kelly
Industry Leader in AAV Technology,
C> Advanced Therapies
Extensive AAV expertise and >25 years experience in Biotech and C> product development, manufacturing, and commercial operations. Recent roles include COO of Homology Medicines, and CEO of OXB Solutions. Experience also at Biogen, UCB, Shire, and Sarepta. Former Fighter Pilot in the US Air Force.
OTHER MEMBERS: To be announced